BEAM · Beam Therapeutics Inc. · Executive Compensation
$20.90
-0.04 (-0.19%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Market Cap
$2.16B
Shares
103.50M
Volume · Nov 20
3.89M
Avg daily vol (3M)
2.05M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| John Evans | CEO | $5,818,525 |
| Giuseppe Ciaramella | President | $3,160,279 |
| Amy Simon | CMO | $2,802,044 |
| Christine Bellon | CLO | $1,967,177 |
| Sravan K. Emany | CFO | $1,296,528 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| John Evans | CEO | $6,409,631 |
| Sravan K. Emany | CFO | $4,818,306 |
| Giuseppe Ciaramella | President | $3,378,647 |
| Terry-Ann Burrell | Former CFO | $2,768,161 |
| Amy Simon | CMO | $2,615,681 |
| Christine Bellon | CLO | $2,581,460 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| John Evans | CEO | $6,280,099 |
| Giuseppe Ciaramella | President | $2,785,194 |
| Terry-Ann Burrell | Former CFO | $2,557,844 |
| Amy Simon | CMO | $2,545,219 |
| Christine Bellon | CLO | $2,281,013 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| John Evans | CEO | $9,496,745 |
| Giuseppe Ciaramella | President | $3,169,575 |
| Terry-Ann Burrell | Former CFO | $2,947,530 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| John Evans | CEO | $13,911,975 |
| Giuseppe Ciaramella | President | $5,535,622 |
| Terry-Ann Burrell | CFO | $3,938,904 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Giuseppe Ciaramella | President | $6,852,786 |
| John Evans | CEO | $906,768 |
| Terry-Ann Burrell | CFO | $683,752 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Terry-Ann Burrell | CFO | $4,302,723 |
| John Evans | CEO | $2,209,800 |
| Giuseppe Ciaramella | President and CSO | $1,588,450 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
|
Carole Ho
“Dr. Ho’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2026-02-05 |
| Sravan K. Emany | Chief Financial Officer | Appointed | 2024-12-06 |
| Chirfi Guindo | member of the Board | Appointed | 2024-12-04 |
| Terry-Ann Burrell | Chief Financial Officer and Treasurer | Resigned | 2024-07-15 |
| Christi Shaw | member of the Board | Appointed | 2023-12-14 |
| John Maraganore | member of the Board | Appointed | 2021-11-08 |
|
Robert Nelsen
“Mr. Nelsen’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2021-05-24 |
|
Stephen Knight, M.D.
“Dr. Knight’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2021-04-23 |
Leadership
- John Evans CEO, Chief Accounting Officer, Board Member
- Sravan Emany CFO
- Sravan K. Emany CFO
- Chirfi Guindo Board Member
- Christi Shaw Board Member
- Graham Cooper Board Member
- John Maraganore Board Member
- John Maraganore, Ph.D. Board Member
- Kathleen Walsh Board Member
- Mark Fishman Board Member
Key facts
CIK
1745999
CUSIP
07373V105
13F (30d)
270 filings
247 filers
Visit website
Investor relations